HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IVVD
Invivyd, Inc.
There isn't enough reported data to score IVVD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IVVD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
IVVD's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IVVD PE Valuation
IVVD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IVVD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect IVVD's revenue to grow, with its earnings and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
IVVD has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus IVVD down 123%.
IVVD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$0.46 | +$1.50 |
| Q2 2025 | -$0.91 | +$0.90 |
| Q1 2025 | -$1.19 | +$0.68 |
| Q4 2024 | -$1.43 | +$0.38 |
| Q3 2024 | -$1.96 | -$0.41 |
| Q2 2024 | -$1.81 | -$0.20 |
| Q1 2024 | -$1.87 | -$0.25 |
| Q4 2023 | -$1.81 | +$0.42 |
IVVD is still losing money, but far less than before: $0.46 per share over the past year, against $3.15 at its worst in mid-2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IVVD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IVVD on profitability, with a higher operating margin.
IVVD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $14.3M | +21% |
| Q1 2026 | $13.7M | +22% |
| Q4 2025 | $17.2M | +25% |
| Q3 2025 | $13.1M | +41% |
| Q2 2025 | $11.8M | +421% |
IVVD's revenue has grown year over year every quarter since mid-2024: $14M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -321% | -193 points |
| Q1 2026 | -314% | -164 points |
| Q4 2025 | -73% | +66 points |
| Q3 2025 | -84% | +586 points |
| Q2 2025 | -128% | +2047 points |
| Q1 2025 | -150% | N/A |
| Q4 2024 | -139% | N/A |
| Q3 2024 | -670% | N/A |
IVVD's operating margin was −321% last quarter, down 193 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IVVD on cash generation, producing positive trailing cash flow while its opponent burns cash.
IVVD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$43.5M | -$30.2M |
| Q1 2026 | -$42.4M | -$21.2M |
| Q4 2025 | -$15.5M | +$22.2M |
| Q3 2025 | -$8.3M | +$32.8M |
| Q2 2025 | -$13.3M | +$28.3M |
| Q1 2025 | -$21.3M | +$29.1M |
| Q4 2024 | -$37.6M | +$21.6M |
| Q3 2024 | -$41.1M | -$5.7M |
IVVD has burned cash in almost every quarter: −$110M over the past year, against −$113M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IVVD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IVVD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.5% | +10.8M shares |
| 1 year | +167% | +201M shares |
| 3 years | +195% | +212M shares |
| 5 years | +407% | +257M shares |
IVVD has 320M diluted shares, up 167% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $1,000 |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IVVD Net Leverage
IVVD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IVVD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 7.0 | Oversold |
IVVD's weekly RSI is 38 (neutral) and its Stochastic is 7 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IVVD PE vs Healthcare Sector
IVVD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IVVD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 16% below |
| 20 week MA | $0.74 | 23% below |
| 50 week MA | $1.29 | 56% below |
| 100 week MA | $1.16 | 51% below |
| 200 week MA | $1.52 | 63% below |
IVVD is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over IVVD on returns for 2026, with the stronger performance.
IVVD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $20.9 | $8.66 | -59% |
| 2022 | $8.66 | $1.70 | -80% |
| 2023 | $1.70 | $3.94 | +132% |
| 2024 | $3.94 | $0.51 | -87% |
| 2025 | $0.51 | $2.69 | +427% |
| 2026 YTD | $2.69 | $0.57 | -79% |
IVVD's yearly returns have swung widely, from +427% in 2025 to −87% in 2024. It's down 79% so far in 2026.